What is Arcus Biosciences's D&A?

Arcus Biosciences (RCUS) reported D&A of $2M in Q1 2026.

How has Arcus Biosciences's D&A changed year-over-year?

Arcus Biosciences's D&A decreased by 33.3% year-over-year, from $3M to $2M.

What is the long-term trend for Arcus Biosciences's D&A?

Over 4 years (2021 to 2025), Arcus Biosciences's D&A has grown at a 25.7% compound annual growth rate (CAGR), from $4M to $10M.

Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.

Arcus Biosciences RCUS D&A

D&A at other companies

Bristol-Myers SquibbBMY

$594M-41.3%

Regeneron PharmaceuticalsREGN

$123.2M-2.9%

ArriVent BioPharma, Inc.AVBP

-$559K+26.1%

ImmunomeIMNM

$603K-1.3%

IDEAYA Biosciences, Inc.IDYA

$688K+14.7%

IncyteINCY

$23.8M+6.4%

Segments

By segment

See full

Reportable segment$2M-33.3%

Other financials

Income statement

See full

Revenue$17.0M-39.3%

Operating income-$134.0M-9.8%

Net income-$128.0M-14.3%

EPS (diluted)-$1.02+10.5%

Balance sheet

See full

Cash & equivalents$201.0M+4.7%

Total debt$113.0M+88.3%

Total equity$524.0M-1.3%

Total assets$997.0M-13.8%

Cash flow

See full

Operating cash flow-$138.0M-4.5%

CapEx--100%

Free cash flow-$138.0M-3.8%

Valuation

See full

Market cap$3.54B+226%

Enterprise value$3.46B+275%

P/S15×+7.3×

Profitability

See full

Operating margin-168.6%-52.7pp

Net margin-156.4%-47.5pp

FCF margin-207.2%—

Returns & leverage

See full

Return on equity-70%+8.4pp

Debt / equity0.2×+0.1×

Current ratio4×-1.3×

Where this comes from

Reported directly by Arcus Biosciences in its filing.

Tagged under the XBRL concept us-gaap:DepreciationAndAmortization.

The official record: Arcus Biosciences’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Arcus Biosciences's d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Arcus Biosciences's D&A?: Arcus Biosciences (RCUS) reported D&A of $2M in Q1 2026.
How has Arcus Biosciences's D&A changed year-over-year?: Arcus Biosciences's D&A decreased by 33.3% year-over-year, from $3M to $2M.
What is the long-term trend for Arcus Biosciences's D&A?: Over 4 years (2021 to 2025), Arcus Biosciences's D&A has grown at a 25.7% compound annual growth rate (CAGR), from $4M to $10M.
What does D&A mean?: Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.